Indeed, since most PD-L1 positive tumors are not affected by anti-PD-1/PD-L1 therapy, the predictive value of PD-L1 in tumor biopsies is so low that it is unacceptable to use as a biomarker in treatment selection [221]. Here, CD274 is linked to neoplasm.